Vielot Nadja A, Bucklin Isabelle K, Westfall Kristy, Kepka Deanna, Zimet Gregory, Zorn Sherri
Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Vaccines (Basel). 2025 Jun 30;13(7):716. doi: 10.3390/vaccines13070716.
: Immunization information systems (IISs) in the United States forecast vaccine due dates, which can inform when providers recommend vaccines to patients. IIS forecasting for HPV vaccination at 9 years, the minimum age of licensure, and when vaccination is likely most effective is not documented or well-understood. : We documented characteristics of HPV vaccination forecasts in jurisdictional IISs through Internet searches and requests to immunization program managers. Next, we conducted focus groups with stakeholders from seven jurisdictions to elucidate their processes for determining and implementing HPV vaccination forecasts. : Forecast data were available from 49 out of 64 CDC-funded jurisdictions, of which 14 (29%) recommended HPV vaccination at age 9 and 35 (71%) recommended HPV vaccination starting at ages 11 through to 15. Jurisdictions that recommended HPV vaccination at age 9 cited the positions of the American Cancer Society and American Academy of Pediatrics and reported little or no provider opposition to this recommendation. Jurisdictions reported variable flexibility in programming their forecasts. Those that changed their HPV vaccination forecast from 11 to 9 years did so easily while some experienced limitations. Other jurisdictions adhered strictly to the CDC's routine recommendation at age 11-12 years and would only update the forecast in tandem with updated CDC guidance. The impact of IISs and electronic health record interoperability on how providers view and utilize IIS forecasting is unclear. : Jurisdictions can share best practices for forecasting at 9 and future studies can evaluate the effects of forecasting age on the vaccination rates, providing evidence for nationwide vaccination recommendations.
美国的免疫信息系统(IISs)可预测疫苗到期日期,这能告知医疗服务提供者何时向患者推荐疫苗。关于9岁(许可接种的最小年龄且接种可能最有效的年龄)人乳头瘤病毒(HPV)疫苗接种的IIS预测,尚无记录或未得到充分理解。
我们通过互联网搜索以及向免疫规划管理人员提出请求,记录了各辖区IISs中HPV疫苗接种预测的特征。接下来,我们与来自七个辖区的利益相关者进行了焦点小组讨论,以阐明他们确定和实施HPV疫苗接种预测的流程。
在疾病控制与预防中心(CDC)资助的64个辖区中,有49个可获取预测数据,其中14个(29%)建议在9岁时接种HPV疫苗,35个(71%)建议从11岁至15岁开始接种HPV疫苗。建议在9岁时接种HPV疫苗的辖区引用了美国癌症协会和美国儿科学会的立场,并报告称医疗服务提供者对此建议几乎没有或没有反对意见。各辖区报告称在规划其预测时灵活性各异。那些将HPV疫苗接种预测从11岁改为9岁的辖区操作起来很容易,而有些则遇到了限制。其他辖区严格遵循CDC在11至12岁的常规建议,并且只会根据CDC的最新指南同步更新预测。IISs和电子健康记录互操作性对医疗服务提供者如何看待和利用IIS预测的影响尚不清楚。
各辖区可以分享9岁时预测的最佳做法,未来的研究可以评估预测年龄对疫苗接种率的影响,为全国性的疫苗接种建议提供证据。